Evaluation of WO2017098421: GSK’s benzothiazine compounds as CD73 inhibitor filings

References

• Lee SY, Fiene A, Li W, et al. Polyoxometalates-potent and selective ecto-nucleotidase inhibitors. Biochem Pharmacol. 2015;93(2):171–181.
   PubMed Web of Science ®Google Scholar
• Zimmermann H. 5’-Nucleotidase: molecular structure and functional aspects. Biochem J. 1992;285(Pt 2):345–365.
   PubMedGoogle Scholar
• Thomson LF, Ruedi M, Glass A, et al. Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol-anchored lymphocyte differentiation antigen ecto-5’-nucleotidase (CD73). Tissue Antigens. 1990;35:9–19.
   PubMedGoogle Scholar
• Resta R, Yamashita Y, Thompson LF. Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol Rev. 1998;161(1):95–109.
   PubMedGoogle Scholar
• Zimmermann H, Zebisch M, Ter NS. Cellular function and molecular structure of ecto-nucleotidases. Purinerg Signal. 2012;8:437–502.
   PubMed Web of Science ®Google Scholar
• Synnestvedt K, Furuta GT, Comerford KM, et al. Ecto-5’-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest. 2002;110(7):993–1002.
   PubMed Web of Science ®Google Scholar
• Stagg J, Divisekera U, Mclaughlin N, et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci USA. 2010;4(107):1547–1552.
   Google Scholar
• Antonioli L, Pacher P, Vizi ES, et al. CD39 and CD73 in immunity and inflammation. Trends Mol Med. 2013;6(19):355–367.
   Google Scholar
• Beavis PA, Stagg J, Darcy PK, et al. CD73: a potent suppressor of anti-tumor immune responses. Trends Immunol. 2012;33(5):231–237.
   PubMed Web of Science ®Google Scholar
• Kumar V. Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go? Purinerg Signal. 2013;9(2):145–165.
   PubMed Web of Science ®Google Scholar
• Jussi N, Tiina H, Gennady G, et al. CD73 (Ecto-5’-Nucleotidase) up-regulation endothelium: a mechanism mediated by IFN-α induced adenosine production on the. J Immunol. 2004;172:1646–1653.
   PubMed Web of Science ®Google Scholar
• Stagg J, Divisekera U, Duret H, et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res. 2011;71(8):2892–2900.
   PubMed Web of Science ®Google Scholar
• Reinhardt J, Landsberg J, Schmid-Burgk JL, et al. MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy. Cancer Res. 2017;77(17):4697–4709.
   PubMed Web of Science ®Google Scholar
• Turcotte M, Allard D, Mittal D, et al. CD73 promotes resistance to HER2/ErbB2 antibody therapy. Cancer Res. 2017. DOI:10.1158/0008-5472.CAN-17-0707.
   Google Scholar
• Allard B, Longhi MS, Robson SC, et al. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol Rev. 2017;276(1):121–144.
   PubMed Web of Science ®Google Scholar
• Antonioli L, Haskó G, Fornai M, et al. Adenosine pathway and cancer: where do we go from here? Expert Opin Ther Tar. 2014;18(9):973–977.
   PubMed Web of Science ®Google Scholar
• Linden J. Molecular approach to a denosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol. 2001;41:775–787.
   PubMed Web of Science ®Google Scholar
• Jin D, Fan J, Wang L, et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. 2010;70(6):2245–2255.
   PubMed Web of Science ®Google Scholar
• Ujházy P, Klobusická M, Babusíková O, et al. Ecto-5’-nucleotidase (CD73) in multidrug-resistant cell lines generated by doxorubicin. Int J Cancer. 1994;59(1):83–93.
   Web of Science ®Google Scholar
• Wang L, Zhou X, Zhou T, et al. Ecto-5’-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin. 2008;134(3):365–372.
   PubMed Web of Science ®Google Scholar
• Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene. 2010;29(39):5346–5358.
   Web of Science ®Google Scholar
• Hoskin DW, Mader JS, Furlong SJ, et al. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells. Int J Oncol. 2008;32(3):527–535.
   PubMed Web of Science ®Google Scholar
• Young A, Mittal D, Stagg J, et al. Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov. 2014;4(8):879–888.
   PubMed Web of Science ®Google Scholar
• Gaudreau PO, Allard B, Turcotte M, et al. CD73-adenosine reduces immune responses and survival in ovarian cancer patients. Oncoimmunology. 2016;5:e1127496.
   PubMed Web of Science ®Google Scholar
• Beavis PA, Slaney CY, Milenkovski N, et al. CD73: a potential biomarker for anti-PD-1 therapy. Oncoimmunology. 2015;4(11):e1046675.
   PubMed Web of Science ®Google Scholar
• Turcotte M, Spring K, Pommey S, et al. CD73 is associated with poor prognosis in high-grade serous ovarian cancer. Cancer Res. 2015;75(21):4494–4503.
   PubMed Web of Science ®Google Scholar
• Loi S, Pommey S, Haibekains B, et al. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci USA. 2013;110(27):11091–11096.
   PubMed Web of Science ®Google Scholar
• Zhang B. Opportunities and challenges for anti-CD73 cancer therapy. Immunotherapy. 2012;4(9):861–865.
   PubMed Web of Science ®Google Scholar
• Stagg J. The double-edge sword effect of anti-CD73 cancer therapy. Oncoimmunology. 2012;2(1):217–218.
   Google Scholar
• Antonioli L, Novitskiy SV, Sachsenmeier KF, et al. Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies. Drug Discov Today. 2017;22(11):1686–1696. pii: S1359-6446(17)30116-2.
   PubMed Web of Science ®Google Scholar
• Stagg J, Beavis PA, Divisekera U, et al. CD73-deficient mice are resistant to carcinogenesis. Cancer Res. 2012;72(9):2190–2196.
   PubMed Web of Science ®Google Scholar
• Antonioli L, Blandizzi C, Pacher P, et al. inflammation and cancer: a leading role for adenosine. Nat Rev Cancer. 2013;13(12):842–857.
   PubMed Web of Science ®Google Scholar
• Regateiro FS, Cobbold SP, Waldmann H. CD73 and adenosine generation in the creation of regulatory microenvironments. Clin Expimmunol. 2013;171(1):1–7.
   PubMed Web of Science ®Google Scholar
• Sorrentino R, Pinto A, Morello S. The adenosinergic system in cancer key therapeutic target. Oncoimmunology. 2013;2:e224481.
   Web of Science ®Google Scholar
• Allard B, Turcotte M, Stagg J. CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. J Biomed Biotechnol. 2012;2012:485156.
   PubMedGoogle Scholar
• Hay CM, Sult E, Huang Q, et al. Targeting CD73 in the tumor microenvironment with MEDI9447. Oncoimmunology. 2016;5:e12088758.
   Web of Science ®Google Scholar
• Abstract 285: MEDI9447: enhancing anti-tumor immunity by targeting CD73 in the tumor microenvironment. 2015 AACR Annual Meeting Abstract 285
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT02503774?cond=MEDI-9447&rank=1
   Google Scholar
• Garcia-Ayllon MS, Campoy FJ, Vidal CJ, et al. Identification of inactive ecto-5’-nucleotidase in normal mouse muscle and its increased activity in dystrophic Lama2dy mice. J Neurosci Res. 2001;66(4):656–665.
   PubMed Web of Science ®Google Scholar
• Grondal EJ, Purification ZH. characterization and cellular localization of 5’-nucleotidase from Torpedo electric organ. Biochem J. 1987;245(3):805–810.
   PubMed Web of Science ®Google Scholar
• Bhattarai S, Freundlieb M, Pippel J, et al. α,β-Methylene-ADP (AOPCP) derivatives and analogues: development of potent and selective ecto-5’-nucleotidase (CD73) inhibitors. J Med Chem. 2015;58(15):6248–6263.
   PubMed Web of Science ®Google Scholar
• Vitae Pharm Inc. Purine derivatives as CD73 inhibitors for the treatment of cancer. WO2015164573. 2015
   Google Scholar
• Arcus Biosciences Inc. Modulators of 5’-nucleotidase, ecto and the use thereof. WO2017120508. 2017
   Google Scholar
• Braganhol E, Tamajusuku ASK, Bernardi A, et al. Ecto-5’-nucleotidase/CD73 inhibition by quercetin in the human U138MG glioma cell line. Biochimica Biophysica Acta. 2007;1770(9):1352–1359.
   PubMed Web of Science ®Google Scholar
• Baqi Y, Lee S, Iqbal J, et al. Development of potent and selective inhibitors of ecto-5’-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010;53(5):2076–2086.
   PubMed Web of Science ®Google Scholar
• Furtmann N, Bajorath J. Evaluation of molecular model-based discovery of ecto-5’-nucleotidase inhibitors on the basis of X-ray structures. Bioorg Med Chem. 2013;21(21):6616–6622.
   PubMed Web of Science ®Google Scholar
• Glaxosmithkline IP Dev Ltd. Benzothiadiazine compounds. WO2017098421. 2017
   Google Scholar
• Abdel-Magid AF. Inhibitors of CD73 may provide a treatment for cancer and autoimmune diseases. ACS Med Chem Lett. 2017;8:781–782.
   PubMed Web of Science ®Google Scholar
• Medimmune Ltd. Binding molecules specific for CD73 and uses thereof. WO2016075099. 2016
   Google Scholar